Opinion on Genomics, Proteomics and Pharmacogenomics

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Inflammatory Bowel Disease: the origin of the feces

Published By Datamonitor
03 Aug 2001
CommentWire
CommentWire

Ingenium: tackling pain with Elan

Elan has formed a collaborative drug development agreement with Ingenium, a functional genomics company. The agreement enhances Elan's drug development capabilities and helps it build a strong CNS pipeline, a key part of its recovery plan.<BR />

Published By Datamonitor
27 Mar 2003
Expert View
Expert View

Inoculating the cancer market

Published By Datamonitor
13 Oct 2000
Expert View
Expert View

Labeling versus drugs in tackling food allergies

Food allergies were first reported 100 years ago, and their reported incidence has been increasing dramatically over the last twenty years. However, food allergy is still an under-researched area, with no curative treatments in the drug pipeline. But is it worth investing in pharmaceutical therapies for food allergy, or will preventative measures work just as well?<BR />

Published By Datamonitor
08 Feb 2002
Expert View
Expert View

Licensing Week - August 9, 2002

Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />

Published By Datamonitor
08 Aug 2002
CommentWire
CommentWire

Millennium Pharma: 'Diagnomics' for melanoma

Published By Datamonitor
15 Jan 2001
Expert View
Expert View

Multiple Sclerosis: the search for a vaccine continues

There are approximately 250,000 to 350,000 diagnosed cases of multiple sclerosis in the US, yet it is estimated that the actual number of Americans with MS may be even higher. As a new approach to the treatment of MS, vaccines have the potential to be both efficacious and cost effective. But can a vaccine be developed as a viable treatment for MS?

Published By Datamonitor
02 Aug 2002
Expert View
Expert View

Needless needles new technologies for vaccine delivery

Published By Datamonitor
11 May 2001
CommentWire
CommentWire

Novuspharma: lending a hand to Micromet

Novuspharma has agreed to co-develop Micromet's MT201, the only fully human antibody in development that targets the Ep-CAM molecule. The companies plan to begin phase II trials for the drug, across a wide range of cancers. Novuspharma's expertise and experience in oncology will aid MT201's development, but the companies will also need an experienced marketing partner.

Published By Datamonitor
02 Sep 2002
Expert View
Expert View

Pharmaceutical Licensing Weekly Review: September 2 - 6, 2002

The week's licensing news has seen pharmaceutical companies becoming involved in agreements across the world. Atrix entered into a licensing deal with Key Oncologics relating to cancer treatments in South Africa whilst Schering-Plough signed a marketing agreement with Shionogi & Co in Japan. In America meanwhile, Enanta and Chiron formed an R&D collaboration as did Aventis and Astex Technology.

Published By Datamonitor
06 Sep 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

No help is available.